Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines for the treatment of human diseases in five therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. It is developing chidamide, a subtype-selective benzamide inhibitor of histone deacetylase (HDAC) primarily targeting subtypes 1, 2, 3 of class I HDAC; chiglitazar, a… Read more
Shenzhen Chipscreen Biosciences Co (688321) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.041x
Based on the latest financial reports, Shenzhen Chipscreen Biosciences Co (688321) has a cash flow conversion efficiency ratio of -0.041x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-72.80 Million) by net assets (CN¥1.78 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shenzhen Chipscreen Biosciences Co - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Shenzhen Chipscreen Biosciences Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shenzhen Chipscreen Biosciences Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Chipscreen Biosciences Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nolato AB (publ)
PINK:NLTBF
|
0.024x |
|
Shanghai Waigaoqiao Free Trade Zone Group Co Ltd A
SHG:600648
|
0.025x |
|
The Navigator Company S.A
PINK:POELF
|
0.026x |
|
G-III Apparel Group Ltd
NASDAQ:GIII
|
0.056x |
|
GUD Holdings Limited
PINK:GUDHF
|
0.060x |
|
Linea Directa Aseguradora SA Compania de Seguros y Reaseguros
MC:LDA
|
0.238x |
|
Toyota Boshoku Corporation
F:TY7
|
0.072x |
|
ATOSS Software SE
F:AOF
|
0.073x |
Annual Cash Flow Conversion Efficiency for Shenzhen Chipscreen Biosciences Co (2016–2024)
The table below shows the annual cash flow conversion efficiency of Shenzhen Chipscreen Biosciences Co from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.58 Billion | CN¥76.13 Million | 0.048x | +152.35% |
| 2023-12-31 | CN¥1.71 Billion | CN¥-157.27 Million | -0.092x | -434.74% |
| 2022-12-31 | CN¥1.58 Billion | CN¥43.30 Million | 0.027x | -68.78% |
| 2021-12-31 | CN¥1.42 Billion | CN¥124.78 Million | 0.088x | +40.45% |
| 2020-12-31 | CN¥1.49 Billion | CN¥93.62 Million | 0.063x | +469.17% |
| 2019-12-31 | CN¥1.45 Billion | CN¥-24.55 Million | -0.017x | -137.09% |
| 2018-12-31 | CN¥497.74 Million | CN¥22.78 Million | 0.046x | +690.06% |
| 2017-12-31 | CN¥471.28 Million | CN¥2.73 Million | 0.006x | -97.75% |
| 2016-12-31 | CN¥232.30 Million | CN¥59.77 Million | 0.257x | -- |